The predictive value of PNH clones, 6p CN-LOH, and clonal TCR gene rearrangement for aplastic anemia diagnosis

Acquired aplastic anemia (AA) is a life-threatening bone marrow failure (BMF) disorder caused by T-lymphocyte–mediated autoimmune attack on hematopoietic stem and progenitor cells (HSPCs).^1-3  Accurate diagnosis of AA followed by prompt, appropriate therapy is imperative for optimal patient outcomes.⁴ Currently, no diagnostic tests can definitively establish the autoimmune etiology of marrow aplasia, and diagnosis instead occurs via the systematic exclusion of alternative causes of BMF.^2,4 Distinguishing immune-mediated BMF (ie, AA) from inherited BMF syndromes (IBMFSs) is particularly challenging. IBMFSs can mimic AA in children and young adults, and patients may present with few extrahematopoietic manifestations and no family history.^5,6 Despite their overlapping clinical presentations, AA and IBMFSs require distinct approaches to treatment and family planning. Specifically, immunosuppressive therapy (IST) that is used to treat immune-mediated AA cannot reverse IBMFS-related marrow aplasia, and misdiagnosis of IBMFSs as AA can delay definitive treatment while exposing patients to serious complications. Patients with undiagnosed IBMFSs may also experience significant bone marrow transplant–related complications with higher-intensity conditioning used for AA or engraftment failure if a related donor carries unrecognized IBMFSs.^5,7,8 

Exclusion of IBMFSs can take multiple weeks. At a minimum, patients should be evaluated for Fanconi anemia (FA) and dyskeratosis congenita (DC) via chromosome breakage and telomere-length analysis, respectively.² Genomic testing for IBMFS-associated variants using next-generation sequencing (NGS) may exclude additional IBMFSs but can significantly delay treatment. Thus, there is a pressing need to develop an efficient diagnostic algorithm that accurately discriminates AA from IBMFSs.

We hypothesized that 3 particular laboratory features tied to the autoimmune pathogenesis of AA could hold high predictive power in discriminating AA from other conditions. Previous studies of clonal hematopoiesis in AA have described 2 recurrent acquired changes in the HSPCs of AA patients: expanded clonal populations with paroxysmal nocturnal hemoglobinuria (PNH) immunophenotype and HLA loss through acquired copy number–neutral loss of heterozygosity of chromosome arm 6p (6p CN-LOH).^3,9-12  These 2 changes are very rare in age-related clonal hematopoiesis^13-15  and are posited to arise specifically in AA by allowing mutant HSPCs to escape autoimmune attack.^9-12  Clonally expanded T-cell populations are another characteristic frequently observed in immune-mediated disorders, including AA, and have been proposed as a diagnostic marker for AA.^16-18  Here, we evaluated the prevalence of PNH, acquired 6p CN-LOH involving the major histocompatibility complex (MHC) region (6p CN-LOH^MHC), and clonal T-cell receptor (TCR) γ gene (TRG) rearrangement, as well as the predictive values of these measures in establishing correct diagnosis, for 454 pediatric and adult patients consecutively enrolled in the retrospective/prospective Children’s Hospital of Philadelphia (CHOP)–University of Pennsylvania (Penn) Bone Marrow Failure Registry. Our results show that PNH and 6p CN-LOH^MHC effectively distinguish AA from IBMFSs and mimicking conditions, whereas clonal TRG rearrangement is not specific for AA.

All 454 pediatric and adult patients referred to the CHOP-Penn Comprehensive Bone Marrow Failure Center and consecutively enrolled in the retrospective/prospective institutional review board (IRB)-approved bi-institutional Bone Marrow Failure Research Study and Repository (Penn IRB #811751; CHOP IRB# 10-007569) from 2010 to 2020 were eligible for this study (supplemental Table 1). Race and ethnicity were self-reported. Informed consent was obtained from all participants or their legal guardians before enrollment in accordance with the Declaration of Helsinki.

Patients were assigned diagnostic groups using standard diagnostic criteria.^19-21  Clinical data were abstracted from the electronic medical record. AA diagnosis was completed by standard criteria, including a bone marrow biopsy examination and metaphase cytogenetic analysis, with fluorescence in situ hybridization performed in case of poor cytogenetic culture growth, followed by systematic exclusion of other disorders and etiologies that mimic AA.^6,20 AA severity was classified using the modified Camitta criteria.^22,23 Patients with isolated hemolytic PNH, as well as PNH that arose from AA (AA/PNH syndrome) with overt hemolysis and large (>30%) PNH granulocyte (PNH^Gran) clones, were grouped into the PNH disease category.²⁴ One PNH disease patient has undergone spontaneous remission, as previously described.²⁵ 

Classical IBMFSs were defined as Shwachman-Diamond syndrome (SDS), DC, Diamond-Blackfan anemia (DBA), FA, and severe congenital neutropenia (SCN). IBMFSs were diagnosed using a combination of clinical diagnoses and syndrome-specific tests, including telomere-length measurement by fluorescence in situ hybridization and flow cytometry for DC, chromosome breakage analysis on lymphocytes or skin fibroblasts for FA, and syndrome-specific genetic testing (supplemental Table 2).^21,26 Patients with other inherited disorders, including inherited hematologic diseases associated with mutations in GATA1 (n = 1), GATA2 (n = 2), SAMD9 (n = 2), SAMD9L (n = 1), and MYH9 (n = 1), as well as Noonan syndrome (n = 1), X-linked agammaglobulinemia (n = 1), hereditary xerocytosis (n = 1), sideroblastic anemia (n = 7), congenital dyserythropoietic anemia (n = 2), glycogen storage disease type I (n = 1), pyruvate kinase deficiency (n = 2), and others (n = 16), were classified as other inherited.

Patients lacking an established, specific IBMFS diagnosis, but clinically diagnosed with a presumed congenital BMF syndrome due to lifelong cytopenias and associated syndromic features, were classified as BMF not otherwise specified (NOS). Isolated neutropenias without an established genetic cause were grouped under neutropenia NOS. Myelodysplastic syndrome (MDS) was diagnosed according to World Health Organization classification criteria.^27,28 Finally, patients evaluated due to a suspicion of BMF, but subsequently diagnosed with other hematologic diseases, were categorized as other; such diagnoses included acute myeloid leukemia, acute lymphoid leukemia, juvenile myelomonocytic leukemia, iron-refractory iron-deficiency anemia, and cytopenias associated with autoimmune conditions.

The presence of PNH clones was established by detection of glycosylphosphatidylinositol (GPI)-anchored protein–deficient granulocytes, monocytes, and erythrocytes using multicolor flow cytometry, as previously described.^29,30 PNH testing was performed as part of the patients’ clinical evaluation by Clinical Laboratory Improvement Amendments (CLIA)-certified flow cytometry laboratories at CHOP, the Hospital of the University of Pennsylvania (HUP), or sendout reference facilities in the course of routine clinical care. PNH clone size was determined as the percentage of GPI-anchor–deficient granulocytes.³⁰ PNH testing performed early in the study enrollment period had a lower limit of quantitation of 1% PNH clone size and evaluated PNH^Gran and PNH erythrocytes. Testing performed after June 2018 used high-resolution PNH flow cytometry with a sensitivity threshold of 0.05% for PNH^Gran, 0.3% for PNH monocytes, and 0.01% for PNH erythrocytes. PNH^Gran clone sizes were used for all comparisons because they were available for all patients and were unaffected by hemolysis or transfusions. Patients with GPI-deficient PNH^Gran were classified into 4 categories based on PNH clone size: subclinical (<1%), small (1% to <10%), moderate (10% to 30%), and large (>30%) (supplemental Table 3). We used a cutoff of PNH^Gran that corresponded to our assay sensitivity (>0.05%) because the presence of even minor PNH populations has been previously shown to be predictive of immunosuppressive therapy response in AA.^31-33  In patients with detectable PNH^Gran clones, the median interval from presentation to first available PNH testing was 0 months (ie, at diagnosis), ranging from initial presentation to 74 months after original diagnosis.

The presence of acquired 6p CN-LOH was ascertained by single-nucleotide polymorphism array (SNP-A) analysis of DNA extracted from bone marrow or peripheral blood samples.³⁴ SNP-A was performed as part of the standard clinical evaluation by CLIA-certified cytogenomic testing facilities at the CHOP Division of Genomic Diagnostics or ARUP Laboratories. Per institutional practice, clinical SNP-A testing was performed at the time of initial evaluation and serially upon diagnostic reevaluation for refractory disease or altered hematologic parameters.³⁴ An additional 34 AA patients and 14 PNH patients were tested on a research basis at the CHOP Center for Applied Genomics using Illumina Global Screening Array genotyping, as previously described.³⁴ The presence of 6p CN-LOH was detected by direct visualization of the B-allele frequency (BAF) and log R ratio in GenomeStudio (Illumina, San Diego, CA). Clonality was determined by examination of BAF, in which patients with large regions of mosaic homozygosity involving the terminus of the short arm of chromosome 6 were classified as having acquired 6p CN-LOH, as previously described (supplemental Table 4).³⁴ Internal regions of homozygosity, with BAF of 1 or 0, were assumed to be constitutional, and they were excluded from the determination of acquired 6p CN-LOH.³⁵ For patients with acquired 6p CN-LOH, the median interval from initial cytopenia to available SNP-A genotyping was 5 months, ranging from initial presentation to 117 months after original diagnosis. Of 16 patients with 6p CN-LOH, 15 had 6p CN-LOH detected on the first available SNP-A, while 1 patient developed 6p CN-LOH upon serial testing.

Clonal TRG rearrangement testing was performed by the HUP CLIA-certified Molecular Diagnostics Laboratory as previously described.³⁶ TRG rearrangement was used to evaluate T-cell clonality because TCR genes rearrange in a stepwise fashion starting with the TRG locus, such that even TCR-β–expressing cells have TRG rearrangements, which can be used as a biomarker of clonality. Compared with the TCR β gene (TRB) polymerase chain reaction (PCR) assay, the TRG PCR assay has less technical complexity and a comparable or superior sensitivity for detecting clonal expansions in patients with T-cell lymphoproliferative neoplasms.^36-38  DNA extracted from peripheral blood or bone marrow specimens was used for PCR detection of clonal variable (V) and joining (J) fragments by amplification across unique VJ junctions with fluorescent primers targeting well-conserved framework regions of TRG V and downstream J segments. After electrophoretic separation, peak sizes and heights were determined. Polyclonal T-cell populations produced Gaussian distributions of peak sizes whereas clonal populations produced distinct peaks. When a prominent peak was observed in an otherwise polyclonal distribution, clonality was interpreted using the ratio of the suspected clonal peak height to the average of the 2 flanking peak heights. All clinical testing was interpreted in a blinded manner, as this study was performed after completion of clinical analysis. Twenty additional samples, selected among IBMFS patients using a random number generator, were tested on a research basis. The interpretation of research samples was performed by a molecular pathologist blinded to the patient diagnosis.

For this study, we used both positive and indeterminate results from the PCR assay as evidence of likely T-cell clonal expansion. Three patients had only TRB PCR results available. Patients with a prior history of solid organ transplant were excluded from TRG analysis.

Clinical test results were compared between diagnostic groups using a 2-tailed Fisher exact test with a significant P value < .05. Odds ratios (ORs) were estimated using the Haldane-Anscombe correction, and the Mantel-Haenszel test was used to compute common ORs across several data sets. Sensitivity, specificity, and positive and negative predictive values were calculated. Likelihood ratios were computed using an adjusted specificity of 0.995 instead of 1.0 to prevent division by zero, and Bayesian nomograms were plotted as previously described.^39,40 

The cohort of 454 pediatric and adult patients included 170 patients with AA, 42 with hemolytic PNH, 109 with classical IBMFSs (DBA, DC, FA, SCN, and SDS), and 38 with other inherited diseases (Table 1; supplemental Table 1). The majority of IBMFS patients had established genetic diagnoses (supplemental Table 2). PNH, 6p CN-LOH, and TRG rearrangement testing results were available for 190, 356, and 160 patients, respectively (Table 1). Metaphase cytogenetics data were available for 377 patients (supplemental Table 5), with 98.0% of AA patients and 91.1% of classical IBMFS patients lacking acquired cytogenetic abnormalities.

To evaluate the predictive value of PNH clones for AA diagnosis, we compared the prevalence of PNH^Gran between AA and other hematologic diseases. PNH^Gran were detected in 58 of 126 AA patients (46%). In contrast, PNH^Gran were not identified in 22 patients with other disorders (OR 38.43; P = .000). Crucially, when compared with classical IBMFS patients, AA patients were significantly more likely to have PNH^Gran (OR 11.10; P = .035). Overall, PNH^Gran provided a positive predictive value (PPV) of 100% and a negative predictive value (NPV) of 48.5%, along with a specificity of 100% and sensitivity of 46.0%, for AA diagnosis and IBMFS exclusion (Table 2). A prior single-institution report showed no PNH^Gran in 20 IBMFS patients, with a similarly high prevalence of PNH^Gran in patients with AA.⁴¹ Combined with our data set, PNH^Gran provided a 100% PPV for AA diagnosis and exclusion of IBMFSs (common OR 25.39; P = .000).

The prevalence of PNH^Gran was similar in pediatric-onset and adult-onset AA patients, and was not associated with disease duration or age at testing. Similarly, there was no correlation of PNH^Gran positivity with AA severity, although PNH^Gran-positive patients had higher marrow cellularity at AA diagnosis (supplemental Table 6).

To ascertain the predictive value of acquired 6p CN-LOH in AA diagnosis, we evaluated SNP-A for 356 patients (Table 1). Sixteen of 141 AA patients (11.3%) had 6p CN-LOH clones, always encompassing the MHC region and HLA genes (supplemental Figure 1; supplemental Table 4). In contrast, none of 215 non-AA patients had acquired 6p CN-LOH (OR 56.67; P = .000). Compared with 74 classical IBMFS patients, none of whom had 6p CN-LOH^MHC, 6p CN-LOH^MHC (regardless of clone size) was significantly more frequent in AA (OR 19.59; P = .002), with a 100% PPV, 63.2% NPV, 100% specificity, and 11.4% sensitivity for AA diagnosis (Table 2).

6p CN-LOH^MHC was detected at similar frequencies in patients across the age spectrum, including 10.3% of pediatric-onset and 12.7% of adult-onset AA patients (P = .786), and was not associated with duration of AA, severity of AA, or marrow cellularity (supplemental Table 6).

In contrast to PNH and 6p CN-LOH, a clinical test of T-lymphocyte clonality, as measured by positive or indeterminate results on the TRG PCR assay, was less specific for AA. We evaluated the presence of clonal TRG rearrangement in 160 patients (Table 3), and in agreement with prior studies showing increased T-cell clonality with age,⁴² we found a higher frequency of clonal TRG rearrangement in older patients (41.5% in adults vs 18.8% in children; OR 3.07; P = .021) (supplemental Table 6).

In comparison with 26 classical IBMFS patients, AA patients were ∽2 times more likely to have clonal TRG rearrangement (29% [26 of 89] vs 15% [4 of 26]; OR 2.27), although this difference was not statistically robust (P = .208). This remained true when adjusting for age (common OR 2.41; P_adj = .231). Overall, clonal TRG rearrangement provided a 50% PPV, 41.7% NPV, 63.4% specificity, and 29.2% sensitivity for the diagnosis of AA and exclusion of IBMFSs (Table 2). In aggregate, clonal TRG rearrangement was ∽3 times more likely in patients with acquired disorders (AA, PNH, neutropenia NOS, and MDS) than in patients with inherited conditions (36.4% [44 of 121] vs 15.6% [5 of 32]; OR 3.09; P = .032); this difference remained significant after age adjustment (common OR 3.16; P_adj = .003).

Of 72 AA patients evaluated for all 3 findings, 46 patients (64%) tested positive for at least 1 (Figure 1A). Forty-one patients (57%) tested positive for either PNH^Gran or 6p CN-LOH^MHC. Most patients with clonal TRG rearrangement also had PNH^Gran (17 patients; 23.6%) or 6p CN-LOH^MHC clones (4 patients; 5.6%).

Because of the shared autoimmune pathogenesis of AA and hemolytic PNH,^43,44 we also evaluated the prevalence and co-occurrence of 6p CN-LOH^MHC and clonal TRG rearrangement in PNH patients. In contrast to AA patients, who had 11% prevalence of 6p CN-LOH^MHC, none of 39 PNH patients had detectable 6p CN-LOH clones (OR 10.39; P = .025) at the level of sensitivity of the SNP-A (∽3% to 5% clone size) (Figure 1B). Conversely, among 13 AA patients who had acquired 6p CN-LOH^MHC, minute PNH^Gran clones were identified in 4 patients, ranging from 0.01% to 1.30% PNH^Gran clone size. None of the AA patients with 6p CN-LOH^MHC developed clinically significant PNH^Gran clones. These data suggest that PNH and 6p CN-LOH^MHC represent alternative means of immune escape in AA, such that having both in the same cell confers no further advantage to the HSPCs, leading to the clonal dominance of 1 or the other immune escape event but not both together.

In agreement with previous reports showing frequent skewing of TCR repertoires in hemolytic PNH disease,^24,45,46 we found a 60% prevalence (12 of 20) of clonal TRG rearrangement in PNH patients. Clonal TRG rearrangement was more prevalent in patients with PNH disease than AA (OR 3.63; P = .018), although this difference was not statistically significant after age adjustment (common OR 3.07; P_adj = .068).

Our study provides a comprehensive analysis of the predictive power of 3 laboratory findings associated with the autoimmune pathogenesis of AA for the diagnosis of immune-mediated AA: PNH clones, acquired 6p CN-LOH^MHC, and clonal TRG rearrangement. Our results demonstrate that PNH and acquired 6p CN-LOH^MHC clones are highly specific for immune-mediated AA, hold a ∽100% PPV for distinguishing immune-mediated AA from IBMFSs, and can facilitate AA diagnosis in up to 57% of patients. Importantly, the absence of PNH and 6p CN-LOH^MHC should not be used to exclude AA, as their NPVs are low (Table 2). In contrast to PNH and acquired 6p CN-LOH^MHC, general T-cell clonality as measured by TRG PCR assay is not specific to AA, is influenced by other clinical factors including age, and can be found in up to 15% of IBMFS patients. The Bayes nomogram for positive PNH^Gran and acquired 6p CN-LOH^MHC demonstrates the tests’ clinical utility in greatly increasing the posttest probability of immune-mediated AA (Figure 2). Our findings support the routine clinical use of PNH and 6p CN-LOH testing early in the diagnostic algorithm to facilitate more efficient diagnosis of immune-mediated AA and to exclude IBMFSs (Figure 3).

Although the pathogenesis of PNH has long been linked to immune-mediated AA,^{3,43,44,47,48} studies examining the predictive value of PNH clones for the diagnosis of AA and exclusion of IBMFSs are sparse. Our data show that PNH^Gran clones are highly specific for immune-mediated AA, with ∽38-fold higher frequency of PNH^Gran in immune-mediated AA compared with other disorders. Our study is the first validation of an earlier single-institutional study that reported no PNH^Gran clones in 20 patients with classical IBMFSs. Combining both studies to increase statistical power, we found that AA patients have ∽25-fold higher odds of expanded PNH^Gran populations compared with IBMFS patients. Although testing in these studies was driven by clinical suspicion of PNH, our results are supported by a previous flow cytometry–based analysis of an unselected cohort of 28 children with SDS and an NGS-based study of 110 SDS patients, which found no PNH clones or PIGA mutations, respectively.^49,50 Two historical cases of patients with presumed FA and PNH have been reported; however, neither used modern testing for FA. In 1944, Dacie and Gilpin described 2 brothers with pancytopenia and hemolysis including features reminiscent of contemporaneous descriptions of FA and PNH; however, neither FA nor PNH were established by modern laboratory testing, and the apparent familial nature of hemolysis challenges PNH diagnosis.⁵¹ In 2003, Wainwright et al reported a patient with severe pancytopenia and PNH clone expansion confirmed by flow cytometry; however, FA diagnosis was rendered despite 2 normal chromosome breakage studies, raising the strong possibility of a false-positive third chromosome breakage test.⁵² Taken together, all available data provide compelling evidence that clonal expansions of PNH^Gran are highly specific to immune-mediated AA and can be used to distinguish AA from IBMFSs.

We and others previously identified somatic HLA loss as a recurrent finding in AA, present in ∽17% of patients.^{10,12,19,53,54} Somatic HLA loss occurs by 2 distinct genetic mechanisms, acquired 6p CN-LOH^MHC or inactivating mutations in HLA class I genes^12,19,54; however, only 6p CN-LOH^MHC is currently amenable to clinical testing by SNP-A genotyping. In contrast, somatic HLA mutation identification requires targeted NGS of HLA genes and specialized bioinformatic analysis,¹² which, at the time of this publication, is not available clinically. Notably, acquired 6p CN-LOH^MHC is the more common mechanism of somatic HLA loss, whereas mutational inactivation of HLA alleles without accompanying 6p CN-LOH occurs in ∽5% of AA patients.¹² We expect that somatic-inactivating mutations in HLA alleles are also specific for AA, and their clinical testing would facilitate AA diagnosis in another ∽5% of AA patients.

Importantly, unlike acquired 6p CN-LOH^MHC, which we found to be highly specific for immune-mediated AA, constitutional homozygosity of 6p and acquired 6p CN-LOH excluding the MHC region are unrelated to AA pathogenesis and should not be used in the diagnostic workup. For instance, a SNP-A analysis of 130 FA patients reported 2 cases of 6p CN-LOH.⁵⁵ However, unlike acquired 6p CN-LOH^MHC in AA, which includes the MHC region and leads to somatic HLA loss, these 2 cases involved the distal end of chromosome 6p with the breakpoints outside of the MHC region (supplemental Figure 1). The same study uncovered no cases of acquired 6p CN-LOH among 15 743 population controls.⁵⁵ Similarly, 2 independent SNP-A analyses found no instances of 6p CN-LOH in 73 FA and 68 DBA patients, respectively.^56,57 To the best of our knowledge, there have been no published reports of acquired 6p CN-LOH^MHC in IBMFSs, reinforcing our findings that it is highly specific to immune-mediated AA.

Although our study focused on distinguishing AA from IBMFSs, our results support the use of PNH and acquired 6p CN-LOH^MHC to identify patients with AA-type immune-mediated marrow failure more broadly. Patients diagnosed with hypocellular MDS or refractory cytopenia of childhood (RCC) may have varying etiologies of marrow dysfunction, including immune-mediated marrow failure, occult IBMFSs, sporadic MDS, and other inherited MDS predisposition syndromes (eg, GATA2 deficiency).^58-62  In fact, a subset of MDS patients was previously reported to have durable objective responses to AA-type IST with horse antithymocyte globulin and cyclosporine.⁶³ Although available studies of immunosuppression in MDS have largely been underpowered, factors predictive of IST response included marrow hypocellularity, young age, HLA-DR15, and PNH clones.^63-65  Similarly, pediatric RCC patients who have PNH clones were previously reported to have improved responses to IST, suggesting that their marrow dysfunction is likely immune-mediated.^33,66 The close link of PNH^Gran and acquired 6p CN-LOH^MHC to the autoimmune pathogenesis of AA can facilitate efficient identification of patients with AA-type autoimmune marrow failure among those diagnosed with RCC or hypoplastic MDS.

This study has limitations. Particularly, this is a retrospective analysis of testing performed as part of routine clinical care. Although not all patients had all 3 laboratory tests completed, each of these findings has been independently evaluated, and our statistical analysis shows significant differences in the frequencies of PNH^Gran and acquired 6p CN-LOH^MHC in AA compared with IBMFSs and other hematologic diseases. Although not all patients had testing performed at initial presentation, the median time from presentation to testing for PNH and 6p CN-LOH was 0 and 5 months, respectively, with all but 1 patient having a positive finding on the first available testing. Notably, the time of testing would not impact the 100% PPV for AA diagnosis, although it may affect the diagnostic sensitivity, as the prevalence of PNH and 6p CN-LOH may rise with disease progression and ongoing treatment. Thus, we recommend the use of serial testing to potentially increase diagnostic yield by affirming AA later in the disease course, a strategy that, alongside repeating a bone marrow biopsy that includes cytogenetic analysis and considering genetic testing for occult IBMFS germline mutations, may be especially helpful in poorly responding patients with enduring diagnostic uncertainty (Figure 3). Furthermore, our study does not include testing for somatic mutations in myeloid malignancy–associated genes. Notably, multiple authoritative analyses have previously shown that somatic mutations occur frequently in healthy aged individuals, as well as in patients with AA, PNH, MDS, and various inherited disorders.^{9,11-14,19,67-71}  Thus, with the noteworthy exception of mutations that lead to PNH clones or acquired HLA loss and are specific to AA, which we describe in this study, MDS-associated mutations have not yet been shown to discriminate AA from IBMFSs effectively, and their utility in the diagnostic evaluation of AA requires further study.

In sum, our study provides a comprehensive analysis of the diagnostic value of PNH, acquired 6p CN-LOH^MHC, and clonal TRG rearrangement for AA in a large cohort of patients with BMF disorders and other hematologic diseases. Our results establish 100% specificity and PPV of both PNH clones and acquired 6p CN-LOH^MHC for the diagnosis of immune-mediated AA. In a clinical setting, discovering either of these 2 markers can significantly increase the posttest probability of immune-mediated AA. In contrast, a positive TRG PCR-based assay of general T-cell clonality is not specific to immune-mediated BMF. Future studies using more sophisticated assays of autoreactive T-cell expansion, perhaps including TRB sequencing or functional assays of T-cell autoreactivity, may help to define the role of T-cell analyses in AA diagnosis. In conclusion, our results support the routine early use of PNH and 6p CN-LOH^MHC testing to effectively distinguish immune-mediated marrow failure from inherited conditions. The next frontier in BMF diagnostics will include combining these 2 current assays of immune-mediated BMF with more sophisticated T-cell analyses and faster, more comprehensive somatic and germline genetic studies to improve the accuracy and efficiency of diagnosis of acquired and inherited BMF disorders.

The authors thank the patients and their families for participation in the Bone Marrow Failure Repository. The authors also thank the clinical care and clinical research administration teams for supporting their work.

This work was supported in part by National Institutes of Health National Heart, Lung, and Blood Institute grant K08 HL132101 (D.V.B.), Department of Defense grant BM170031 (T.S.O.), the Institute for Translational Medicine and Therapeutics of the Perelman School of Medicine at the University of Pennsylvania, and National Institutes of Health National Center for Advancing Translational Sciences grant UL1TR001878 (D.V.B. and T.S.O.).

Contribution: Y.B.S. and D.V.B. collected and analyzed the data, performed literature review, and wrote and revised the manuscript; S.F.P. and C.N.T. performed TRG rearrangement analysis; Y.L. performed statistical review; P.N., T.S.O., and D.V.B. enrolled patients, processed and provided critical patient samples, and oversaw the human subjects aspects of the research; P.K. and T.S.O. provided pediatric BMF expertise; D.V.B. conceived and oversaw the study; and all authors edited and approved the final version of the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Daria V. Babushok, Division of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Room 808 BRB II/III, 421 Curie Blvd, Philadelphia, PA 19104; e-mail: daria.babushok@pennmedicine.upenn.edu.